Form 8-K - Current report:
SEC Accession No. 0001193125-24-262103
Filing Date
2024-11-20
Accepted
2024-11-20 06:40:29
Documents
14
Period of Report
2024-11-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d873020d8k.htm   iXBRL 8-K 23975
2 EX-99.1 d873020dex991.htm EX-99.1 10901
  Complete submission text file 0001193125-24-262103.txt   156841

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20241120.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20241120_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20241120_pre.xml EX-101.PRE 10812
17 EXTRACTED XBRL INSTANCE DOCUMENT d873020d8k_htm.xml XML 3555
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 241478235
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)